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Introduction
Many immune system cells detect the direction and intensity 
of an extracellular chemical gradient, and migrate toward the 
source of stimulus. This process, called chemotaxis, is essential 
for immune system function and homeostasis, and its deregulation 
is associated with chronic infl  ammation. Migrating cells are 
morphologically and functionally asymmetric, with two oppo-
site compartments: the leading edge at the front and the uropod at 
the rear. Establishing and maintaining cell polarity in response 
to extracellular stimuli appear to be mediated by feedback loops 
involving phosphatidylinositol 3-kinases (PI3Ks), the Rho family 
of small GTPases, integrins, microtubules, and vesicular trans-
port (Ridley et al., 2003; Charest and Firtel, 2006; Willard and 
Devreotes, 2006). These feedback loops are regulated in turn by 
the asymmetric distribution of cell membrane microdomains dur-
ing migration (Gómez-Moutón et al., 2001, 2004; Mañes and 
Viola, 2006; Nuzzi et al., 2007).
Dynamic remodeling of actin cytoskeletal elements, which 
is controlled by the Rho family of GTPases, is a driving force 
for immune cell polarization and migration. Rac and Cdc42 
GTPases are associated with leading edge protrusion and orien-
tation of migration (Ridley et al., 2003; Willard and Devreotes, 
2006); in contrast, RhoA is implicated in uropod formation 
(Yoshinaga-Ohara et al., 2002; Xu et al., 2003; Lee et al., 2004). 
RhoA activates ROCK (p160-Rho-associated coil-containing 
protein kinase), which phosphorylates myosin light chains (MLC) 
and thus increases actin fi  lament contraction (Alblas et al., 2001; 
Worthylake et al., 2001). Local ATP production by mitochondria 
regulates myosin II phosphorylation (Campello et al., 2006).
The mechanisms by which RhoA and Rac/Cdc42 seg-
regate to opposite poles are not well understood. In DMSO-
differentiated HL60 cells (dHL60; a neutrophil-like cell line), 
mutual suppression of one GTPase by the other was proposed 
to allow Rac to predominate at the leading edge and RhoA at 
the uropod (Xu et al., 2003). Rac activation at the uropod has 
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irectional cell movement in response to external 
chemical gradients requires establishment of front–
rear asymmetry, which distinguishes an up-gradient 
protrusive leading edge, where Rac-induced F-actin poly-
merization takes place, and a down-gradient retractile 
tail (uropod in leukocytes), where RhoA-mediated acto-
myosin contraction occurs. The signals that govern this 
spatial and functional asymmetry are not entirely under-
stood. We show that the human type I phosphatidylinositol 
4-phosphate 5-kinase isoform β (PIPKIβ) has a role in 
  organizing signaling at the cell rear. We found that PIPKIβ 
polarized at the uropod of neutrophil-differentiated HL60 
cells. PIPKIβ localization was independent of its lipid kinase 
activity, but required the 83 C-terminal amino acids, which 
are not homologous to other PIPKI isoforms. The PIPKIβ 
C terminus interacted with EBP50 (4.1-ezrin-radixin-moesin 
(ERM)-binding phosphoprotein 50), which enabled fur-
ther interactions with ERM proteins and the Rho-GDP dis-
sociation inhibitor (RhoGDI). Knockdown of PIPKIβ with 
siRNA inhibited cell polarization and impaired cell direc-
tionality during dHL60 chemotaxis, suggesting a role for 
PIPKIβ in these processes.
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nonetheless been reported (Gardiner et al., 2002). The signaling 
pathways   involved in Rac/Cdc42 and RhoA activation are only 
partially defi  ned. In dHL60 and Jurkat T cells, chemoattractant 
receptors simultaneously initiate two divergent signals, activat-
ing Rac/Cdc42 (via trimeric Gi proteins) at the leading edge and 
RhoA (via trimeric G12/G13 proteins) at the uropod (Xu et al., 
2003; Tan et al., 2006). Nonetheless, signaling pathways spe-
cifically triggered at the cell front may also activate RhoA at 
the uropod (Van Keymeulen et al., 2006; Filippi et al., 2007). 
In T cells, ERM proteins exercise control over RhoA activation 
and  uropod formation (Lee et al., 2004), and can also be a down-
stream target of the RhoA/ROCK pathway (Yonemura et al., 
2002; Yoshinaga-Ohara et al., 2002). This apparently contradic-
tory evidence suggests a requirement for additional signaling 
pathways to establish front–rear cell polarity.
The lipid phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2] 
might be a key participant in the integration of the front–rear 
signaling. At the leading edge, PI(4,5)P2 is a substrate shared by 
PI3K and PLC. PI(4,5)P2 phosphorylation by PI3K generates 
phosphatidylinositol 3,4,5-triphosphate (PIP3), a hallmark of the 
leading edge in polarized neutrophils (Ridley et al., 2003; Mañes 
et al., 2005). Antagonism between PI3K and the PIP3 phosphatase 
PTEN (phosphatase and tensin homologue on chromosome 10) 
was proposed as a guidance system for directed migration of 
the amoeba Dictyostelium (Ridley et al., 2003), but its impor-
tance in leukocyte chemotaxis is debated (Lacalle et al., 2004; 
Nombela-Arrieta et al., 2004; Li et al., 2005; Van Keymeulen 
et al., 2006; Nishio et al., 2007). PI(4,5)P2 hydrolysis by PLC 
generates inositol 1,4,5-triphosphate and diacylglycerol (DAG), 
necessary for Ca
2+ mobilization into cells and PKC activation, 
respectively (Rebecchi and Pentyala, 2000). PLC activity is 
needed for T cell chemotaxis via a Ca
2+-independent/DAG-
dependent mechanism (Cronshaw et al., 2006). PI(4,5)P2 may 
also regulate cofi  lin location at the pseudopodia of carcinoma 
cells, proposed as another guidance system (Mouneimne et al., 
2006). At the uropod, PI(4,5)P2 is a major regulator of ERM 
protein activation of chemotaxing leukocytes (Yonemura et al., 
2002; Fievet et al., 2004), and directly regulates many actin-
binding and actin-remodeling proteins, including Rho GTPases 
(Caroni, 2001; Ling et al., 2006). Given the high steady-state 
level of PI(4,5)P2 and the broad range of its potential targets, 
functional compartmentalization of PI(4,5)P2 inside the cell may 
be crucial during chemotaxis.
Although PI(4,5)P2 can be synthesized from PI(5)P (Rameh 
et al., 1997), the main biosynthetic pathway is regulated 
by the so-called type I phosphatidylinositol-phosphate kinases 
(PIPKIs), which use PI(4)P as substrate and thus function 
as PI(4)P-5 kinases (Ishihara et al., 1998). There are three 
PIPKI isoforms (α, β, and γ); human PIPKIα is equivalent 
to the mouse PIPKIβ isoform and vice versa (to avoid con-
fusion, we will use human nomenclature in this manuscript). 
There are also at least two PIPKIγ isoforms (PIPKIγ
635 and 
PIPKIγ
661), generated by alternative splicing. In fi  broblasts, the 
three PIPKI isoforms have distinct subcellular locations (Ling 
et al., 2006).
Here, we found that the human PIPKIβ isoform localizes 
to the uropod of polarized dHL60 cells; this polarized distribution 
requires the PIPKIβ C-terminal domain. At the uropod, PIPKIβ 
may serve as a scaffold for interaction among several proteins 
including, but not limited to, EBP50, ERM, and RhoGDI. PIPKIβ 
knockdown impaired cell polarity and directionality during 
chemotaxis. We thus propose PIPKIβ as a new element involved 
in a positive feedback loop that regulates directional leuko-
cyte motility by organizing specifi  c signaling pathways at the 
cell posterior.
Results
Human PIPKI𝗃 localizes to the uropod of 
polarized dHL60 cells
To study PI(4,5)P2 compartmentalization in leukocyte chemo-
taxis, we used real-time videomicroscopy to analyze local-
ization of the mouse orthologues for three GFP-tagged PIPKI 
isoforms (PIPKIα, PIPKIβ, and PIPKIγ
635) in dHL60 cell 
chemotaxis   toward the neutrophil chemoattractant N-formyl-
methionyl-leucyl-phenylalanine (fMLP). We found that as the 
cells polarized, GFP-PIPKIβ accumulated almost exclusively at 
the sides and back of moving cells (Fig. 1 A; Video 1, available 
at http://www.jcb.org/cgi/content/full/jcb.200705044/DC1).
In contrast, GFP-PIPKIα and GFP-PIPKIγ
635 homogeneously 
stained the cytosol and/or membrane, with no specific cell 
pole dom  inance during chemotaxis (Fig. 1 A; Videos 2 and 3). 
HA-tagged PIPKIβ also localized at the uropod of fMLP-
stimulated dHL60 cells, indicating that uropod localization of 
this PIPK isoform was not the consequence of GFP fusion 
(Fig. S1 A, avail  able at http://www.jcb.org/cgi/content/full/
jcb.200705044/DC1). Immuno  fl  uorescence analysis of endog-
enous PIPKI isoforms in f  MLP-stimulated dHL60 cells suggested 
PIPKIβ accumulation at the uropod (Fig. 1 B; Fig. S1 B). Finally, 
GFP-tagged PIPKIβ was confi  ned at the uropod of Jurkat T cells 
polarized by CXCL12 stimulation, indicating that PIPKIβ local-
ization at the cell rear is found in different cell types (Fig. S1 C).
PIPKI𝗃 is required for dHL60 cell polarity 
and chemotaxis
To address the relevance of PIPKIβ in chemotaxis, we trans-
fected dHL60 cells with mismatched or PIPKIβ-specifi  c siRNA. 
Two different PIPKIβ-siRNAs reduced mRNA levels specifi  -
cally for PIPKIβ, but did not affect the other PIPKI isoforms 
(Fig. 2 A); moreover, these PIPKIβ siRNAs reduced PIPKIβ 
protein levels (Fig. 2 B). Targeting of endogenous PIPKIβ sig-
nifi  cantly reduced dHL60 cell polarization, as determined by 
the concurrent loss of F-actin accumulation at the leading edge 
and of phosphorylated-ERM (p-ERM) at the   uropod (Fig. 2 C). 
Moreover, PIPKIβ-specifi  c, but not mismatched siRNA, re-
duced dHL60 chemotaxis toward f  MLP in a transwell assay 
(Fig. 2 D). To further analyze the role of PIPKIβ in chemotaxis, 
we performed time-lapse chemotactic assays of control and 
PIPKIβ-specific siRNA-transfected dHL60 cells. PIPKIβ-
specifi  c siRNA signifi  cantly impaired persistence during migration 
(0.85 ± 0.02 vs. 0.69 ± 0.03, for control and PIPKIβ siRNA-
transfected cells, respectively; P  <0.001, two-tailed t test), but 
did not affect cell speed (7.84 ± 0.34 μm/min for control, 8.17 ± 
0.6 μm/min for PIPKIβ-siRNA, P = 0.63, two-tailed t test; PIPKIβ CONTROLS NEUTROPHIL POLARITY • LACALLE ET AL. 1541
Fig. 2 E). The mean   translocation rate over a 7-min period was 
also higher in PIPKIβ siRNA (11.26 ± 0.41 μm/min) than in 
control siRNA (9.89 ± 0.49 μm/min) transfected cells (P = 
0.07, two-tailed t test). These results suggest a role for endoge-
nously expressed PIPKIβ in the chemoattractant-elicited leuko-
cyte cell polarity program.
Signaling pathways involved in uropod 
accumulation of PIPKI𝗃
Chemoattractant stimulation in leukocytes appears to generate   
two opposing signals, mediated by different trimeric G proteins; 
pertussis toxin (PTX)-sensitive Gi proteins activate leading 
edge signaling pathways, and PTX-insensitive G12/G13 elicit the 
Figure 1. Human  PIPKI𝗃 polarizes to the uropod during dHL60 cell chemotaxis. (A) Time-lapse Nomarski and ﬂ  uorescent images of dHL60 cells expressing 
GFP-tagged PIPKIα, PIPKIβ, and PIPKIγ
635 isoforms migrating toward an fMLP-loaded micropipette. Time in seconds from the ﬁ  rst frame (0 s). (B) Immunoﬂ  uor-
escence analysis of endogenous PIPKI isoforms in uniformly stimulated dHL60 cells. Bar, 10 μm. Results are representative of at least 20 cells recorded in 
each of three independent experiments.JCB • VOLUME 179 • NUMBER 7 • 2007  1542
Figure 2. PIPKI𝗃 knockdown inhibits dHL60 cell polarization and chemotaxis. (A) PIPKIβ knockdown in dHL60 cells 48 h after transfection with 50 nM 
control or PIPKIβ-speciﬁ  c siRNA, as determined by quantitative RT-PCR (see Materials and methods). The results are normalized to the relative PIPKIβ mRNA 
levels in cells transfected with control siRNA (representative of ﬁ  ve experiments). (B) Crude lysates (80 μg/lane) from cells as in A were analyzed by immuno-
blot with anti-PIPKIβ and anti-actin antibodies. The graph represents mean ± SEM of densitometry values for the PIPKIβ band from three independent 
  experiments, taking the band in siRNA control cells as 100%. (C) Cell polarity depends on PIPKIβ. Uniformly stimulated dHL60 cells transfected with control 
or two PIPKIβ-speciﬁ  c siRNA were stained with phalloidin (red) and phospho-ERM proteins (green) as leading edge and uropod markers, respectively. Only 
cells showing clear segregation of phalloidin and phospho-ERM proteins were scored as polarized. Data are mean ± SEM of the percentage of polarized 
cells from three independent experiments. Representative ﬁ  elds for each condition are shown (left panels). Bar, 10 μm. (D) Cell chemotaxis depends on 
PIPKIβ. Chemotaxis was analyzed for Cy3-labeled control or PIPKIβ-speciﬁ  c siRNA-transfected dHL60 cells in transwell assays (see Materials and methods). 
Data are mean ± SEM (expressed as percentage) of cells migrating toward fMLP in three independent experiments. (*, P < 0.01; two-tailed t-test). (E) Rep-
resentative examples of migration tracks of control or PIPKIβ-speciﬁ  c siRNA-transfected cells chemotaxing toward fMLP. In these and subsequent composite 
migration ﬁ  gures, randomly selected individual migration tracks were copied and combined into a single ﬁ  gure. The white dot represents the fMLP-loaded 
pipette tip; bar, 10 μm. Right panels show quantiﬁ  cation of the persistence of migratory directionality and velocity of control or PIPKIβ siRNA-transfected 
cells. D/T ratios represent the ratio of the direct distance from start to end point [D] divided by total track distance [T]. Velocity was calculated as total dis-
tance divided by time (μm/min). Data were pooled from three independent experiments; error bars indicate SEM based on n = 22–25 cells (*, P < 0.001; 
two-tailed t test).PIPKIβ CONTROLS NEUTROPHIL POLARITY • LACALLE ET AL. 1543
signals that shape the uropod (Xu et al., 2003; Tan et al., 2006). 
PTX treatment of dHL60 cells did not prevent fMLP-induced 
PIPKIβ accumulation at the uropod (Fig. 3 A; quantifi  cation in 
Fig. 3 F). Overexpression of the C terminus of Gα12 and Gα13, or 
of the catalytically inactive Gα12
(Q209L/D277N) and Gα13
(Q226L/D294N) 
mutants, prevented PIPKIβ polarization (Fig. 3, B and C).
We analyzed PIPKIβ polarization in dHL60 cells express-
ing a dominant-negative RhoA mutant (RhoAN19).   Although 
RhoAN19 overexpression altered the dHL60 cell phenotype, 
PIPKIβ concentration at the uropod persisted in a large proportion 
of cells (Fig. 3 D). ROCK is a major RhoA target, and controls 
actomyosin contraction by regulating the phosphorylation state of 
MLC (Kimura et al., 1996). Cell treatment with the ROCK inhibi-
tor Y-27632 resulted in cells with extended uropods, probably due 
to the inability of the cell to retract the rear; indeed, Y-27632 treat-
ment greatly   reduced dHL60 cell migration (unpublished data). 
PIPKIβ was localized diffusely in these long uropods, but was ex-
cluded from the leading edge (Fig. 3 E), indicating that ROCK in-
hibition did not prevent PIPKIβ polarization. These results suggest 
that PIPKIβ polarization is independent of RhoA signaling.
The PIPKI𝗃 C terminus acts as a uropod-
targeting sequence
We studied the molecular determinants for specifi  c PIPKIβ 
recruitment to the uropod. PIPKI has a conserved kinase homology 
domain (KHD) and sequence-divergent N and C termini; we 
thus performed mutagenesis analysis that affected each of these 
regions (Fig. 4 A). Lipid kinase activity appeared not to be 
required for PIPKIβ-specific location, as the kinase-dead 
PIPKIβ
K138A mutant (Itoh et al., 2000) concentrated at the uropod 
of polarized cells, as did PIPKIβwt (Fig. 4, B and C; Fig. S1 D). 
Many PIPKIβ
K138A-expressing cells nonetheless had longer 
tails than PIPKIβwt-expressing cells (Video 4, available at 
http://www.jcb.org/cgi/content/full/jcb.200705044/DC1). Con-
sistent with this impairment in tail retraction, cell speed was re-
duced in PIPKIβ
K138A-expressing dHL60 cells compared with 
mock- or PIPKIβwt-expressing cells (7.0 ± 0.6 μm/min for 
PIPKIβwt vs. 3.9 ± 0.3 μm/min for the PIPKIβ
K138A mutant; 
Fig. 4 J). PIPKIβ
K138A-expressing cells also showed a signifi  cant 
reduction in directionality compared with PIPKIβwt-expressing 
cells (Fig. 4, I and J).
Within the KHD, the activation loop (PIPKIβ amino acids 
355–376) confers substrate specifi  city, whereas K
397 and K
398 
are important for membrane anchoring (Arioka et al., 2004). 
In PIPKIγ, the KHD N-terminal portion is also required for mem-
brane association (Arioka et al., 2004), suggesting that the KHD 
is necessary and suffi  cient for plasma membrane localization. Our 
results confi  rmed these observations, as GFP-tagged PIPKIβ∆34 
(Fig. 4 D) and PIPKIβ∆395 (Fig. 4 E) deletion mutants localized 
to cytosol. These mutants were also homogeneously distributed in 
Figure 3.  Signaling pathways involved in PIPKI𝗃 polarization. Polarization of GFP- or RFP-tagged PIPKIβ was analyzed in fMLP-stimulated dHL60 cells after 
treatment with PTX (A), overexpression of dominant-negative Gα12 and Gα13 mutants (B), overexpression of the catalytically inactive Gα12
(Q209L/D277N) and 
Gα13
(Q226L/D294N) mutants (C), dominant-negative GFP-RhoAN19 mutant (D), or after treatment with ROCK inhibitor Y-27632 (E). Mock-transfected or vehicle-treated 
cells were analyzed in parallel. Representative cells in each experimental condition are shown; bar, 10 μm. (F) Quantiﬁ  cation of the effect on PIPKIβ polarization of 
the inhibitors or mutants tested. Data are mean ± SEM from three independent experiments; at least 30 cells were recorded in each experiment for each condition.JCB • VOLUME 179 • NUMBER 7 • 2007  1544
polarized cells, indicating that plasma membrane association is a 
major determinant for PIPKIβ polarization at the uropod.
The PIPKIβ∆456 mutant, which retains KHD but lacks 
the last 83 amino acids (83aa-tail), retained membrane associa-
tion but was homogeneously distributed in fMLP-stimulated 
cells (Fig. 4 F). To further confi  rm the role of this 83aa-tail in 
uropod targeting, we produced a chimeric protein by fusing the 
83aa-tail of PIPKIβ to a C terminus–deleted PIPKIγ mutant 
(PIPKIγ
1-502). PIPKIγ
1–502 stained the cell periphery evenly 
(Fig. 4 G; Video 5, available at http://www.jcb.org/cgi/content/
full/jcb.200705044/DC1); introduction of the 83aa-tail from the 
β isoform into this mutant (PIPKIγ
1–502β
455–539) was suffi  cient to 
redirect this chimera to the uropod (Fig. 4 H; Video 6), indicating 
the relevance of the PIPKIβ C terminus for uropod polarization. 
When expressed alone in dHL60 cells, the 83aa-tail localized 
in the perinuclear region (unpublished data), supporting the idea 
that PIPKIβ localization at the uropod requires kinase binding 
to the plasma membrane.
We also observed dose-dependent inhibition of chemo-
attractant-induced cell asymmetry by PIPKIβ∆456 overexpression. 
Time-lapse experiments indicated that PIPKIβ∆456-expressing 
cells were unable to chemotax toward fMLP, showing a severe 
reduction in cell directionality and speed (Fig. 4, I and J). 
Introduction of the 83aa-tail in the chimera PIPKIγ
1–502β
455–539 
restored cell velocity (6.1 ± 0.5 μm/min), although directionality 
was reduced compared with PIPKIβwt-expressing cells (0.83 
for PIPKIβwt vs. 0.75 for PIPKIγ
1–502β
455–539; Fig. 4 J; border-
line signifi  cance). This small difference in directional persis-
tence in PIPKIγ
1–502β
455–539-expressing cells suggests nontotally 
overlapping functions for other domains of PIPKIβ and PIPKIγ 
isoforms in cell chemotaxis.
Overexpression of the PIPKI𝗃𝖫456 mutant 
prevents cell orientation toward a gradient
To further study the loss of polarity induced by PIPKIβ∆456 over-
expression, we analyzed the asymmetry of early fMLP-induced 
signals. The AKT-PH domain (AKT-PH-GFP) is recruited per-
sistently at the up-gradient edge in dHL60 cells (Gómez-Moutón 
et al., 2004), and this pattern was not changed by PIPKIβwt 
overexpression (Fig. 5 A; Video 7, available at http://www.jcb
.org/cgi/content/full/jcb.200705044/DC1). In PIPKIβ∆456-
overexpressing cells, AKT-PH-GFP was recruited simultaneously 
to pseudopods formed on the cell down- and up-gradient sides 
(Fig. 5 B; Video 8). We also analyzed the dynamics of the GFP-
tagged Pak-1 binding domain (PBD-GFP) to monitor active Rac, 
a pathway involved in leading edge formation. PBD-GFP cycled 
between the cytosol and the membrane exclusively at the leading 
edge of PIPKIβwt-expressing cells during chemotaxis (Fig. 5 C; 
Video 9). In PIPKIβ∆456 cells, however, PBD-GFP was re-
cruited very transiently to pseudopods that formed around the cell 
perimeter (Fig. 5 D; Video 10). Together, these results indicate 
that PIPKIβ∆456 prevents morphological and functional polar-
ization of chemoattractant-stimulated dHL60 cells, even though 
these cells express endogenous PIPKIβ.
PIPKIβ∆456 might induce this dominant-negative effect 
on cell polarity by deregulating PI(4,5)P2 levels. PIPKIβ∆456 
retains intact KHD and the activation loop, and therefore this 
mutant might retain the ability to produce PI(4,5)P2. To ad-
dress this point, we performed an in vitro kinase assay using 
HA-PIPKIβwt and HA-PIPKIβ∆456 immunoprecipitated from 
HEK-293 cells before or after stimulation with the chemo-
attractant CXCL12. Both HA-PIPKIβwt and HA-PIPKIβ∆456 
showed basal kinase activity in unstimulated cells, which in-
creased after chemoattractant stimulation (Fig. 5 E). Generation 
of PI(4,5)P2 was not observed in immunoprecipitates of the 
kinase-dead HA-PIPKIβ
K138A or HA-PIPKIβ∆456
K138A mutants, 
indicating kinase assay specifi  city (Fig. 5 E). These results thus 
suggest that chemoattractants stimulate PIPKIβ lipid kinase 
activity. Chemoattractant stimulation nonetheless did not in-
crease total PI(4,5)P2 levels in PIPKIβwt- or HA-PIPKIβ∆456-
  expressing cells (Fig. S2 A, available at http://www.jcb.org/cgi/
content/full/jcb.200705044/DC1); furthermore, total PI(4,5)P2 
levels were not increased by PIPKIβwt or HA-PIPKIβ∆456 
overexpression, compared with mock-transfected cells.
We thus analyzed local changes in PI(4,5)P2 during 
PIPKIβwt- and PIPKIβ∆456-expressing dHL60 cell chemotaxis 
using the pleckstrin homology (PH) domain of PLCδ tagged 
with GFP (GFP-PH-PLCδ). Overexpression of GFP-PH-PLCδ 
drastically inhibited chemotaxis in these cells (unpublished data), 
however, compromising data interpretation. A considerable 
proportion of GFP-PH-PLCδ–expressing dHL60 still polar-
i  zed after homogeneous stimulation with fMLP. In polarized 
mock and RFP-PIPKIβwt-expressing cells, GFP-PH-PLCδ ac-
cumulated at the leading edge and the uropod (Fig. S2, B and C). 
In contrast, PI(4,5)P2 co-redistributed with RFP-PIPKIβ∆456 
in random patches in the periphery of PIPKIβ∆456-expressing 
cells (Fig. S2 D).
Because chemoattractants stimulate PIPKIβ∆456-mediated 
PI(4,5)P2 production, PIPKIβ∆456 might prevent dHL60 cell 
polarization by “delocalizing” the source of PI(4,5)P2; elevated 
PI(4,5)P2 levels might in turn generate PIP3 at inappropriate cell 
sites. A kinase-dead version of PIPKIβ∆456 (PIPKIβ∆456
K138A) 
nonetheless inhibited fMLP-induced dHL60 cell polarization as 
effi  ciently as the kinase-active PIPKIβ∆456 (Fig. 5 F); moreover, 
fMLP-induced AKT phosphorylation, an indirect readout of PIP3 
levels, was comparable in cells expressing the kinase-active or 
kinase-dead mutants (Fig. S2 E). These results indicate that the 
dominant-negative effects of PIPKIβ∆456 on cell polarity are 
independent of its lipid kinase activity. PIPKIβwt overexpres-
sion also restored fMLP-induced cell polarity in PIPKIβ∆456-
expressing dHL60 cells (Fig. 5 G), suggesting that through a region 
distinct from the C terminus, PIPKIβ binds to other protein(s) with 
an important role in cell polarity.
Overexpression of the PIPKI𝗃𝖫456 mutant 
inhibits RhoA activation at the uropod
We found that PIPKIβ∆456 overexpression resulted in homog-
eneous, largely cytosolic distribution of RhoA after uniform 
fMLP stimulation, which contrasted with the uropod RhoA dis-
tribution in PIPKIβwt-expressing cells (Fig. 6 A). Stimula-
tion of untransfected dHL60 or HEK-293 cells with fMLP 
or the chemokine CXCL12, respectively, induced a transient 
in  crease in RhoA activity after 30–60 s (Fig. S3A, available 
at http://www.jcb.org/cgi/content/full/jcb.200705044/DC1). PIPKIβ CONTROLS NEUTROPHIL POLARITY • LACALLE ET AL. 1545
Figure 4.  Polarization of PIPKI𝗃 to the cell uropod requires the C terminus. (A) Scheme of the PIPKIβ mutants and chimeras used. The KHD is shown in pas-
tel colors; the activation loop (AL) is delimited by dashed lines. The K
138A mutation is indicated by a solid line. (B–H) subcellular distribution of the different 
GFP-tagged mutants in polarized dHL60 cells after uniform stimulation with fMLP. Cells are representative of at least 20 cells recorded in three independent 
experiments; bar, 10 μm. (I) Composite collection of representative tracks for fMLP-induced migration of dHL60 cells expressing the indicated PIPKIβ 
  mutants; bar, 10 μm. (J) Quantiﬁ  cation of persistence of migratory directionality (D/T) and velocity of the transfected cells. Data (mean ± SEM) were obtained 
from video time-lapse microscopy of a total of 18–25 cells. Probability was calculated by two-tailed t-test and is indicated for the corresponding mutants. 
The mean translocation rates (± SEM), calculated as total cell migration over 2–5-min periods (or 2–8 min for the PIPKIβ
K138A mutant), were 16.1 ± 0.75, 
13.57 ± 0.66, 6.11 ± 0.62, 4.47 ± 0.27, and 11.08 ± 0.57 μm/min for mock-, PIPKIβwt-, PIPKIβ
K138A-, PIPKIβ∆456-, and PIPKIγ
1–502β
455–539-expressing 
cells, respectively.JCB • VOLUME 179 • NUMBER 7 • 2007  1546
Figure 5.  Overexpression of PIPKI𝗃𝖫456 prevents dHL60 cell polarity. (A–D) PI3K and Rac activation were analyzed by time-lapse video microscopy of 
RFP-PIPKIβwt- and RFP-PIPKIβ∆456-expressing dHL60 cells, using the AKT-PH-GFP (A and B) and the PBD-GFP (C and D) domains as probes for PI3K and 
Rac, respectively. Time-lapse images for Nomarski and red-green channel merge are shown. In D, micropipette location is indicated by a black dot; arrow-
heads indicate areas of the membrane recruiting the PBD-GFP probe. The cells shown are representative of at least 30 recorded in three independent 
experiments. (E) Chemoattractants stimulate PIPKIβ- and PIPKIβ∆456-induced PI(4,5)P2 production. HA-tagged PIPKIβ constructs as indicated were immuno-
precipitated from starved or CXCL12-stimulated HEK-293 cells; kinase activity was analyzed in an in vitro kinase assay using PI(4)P as substrate. The same 
cell extracts were analyzed by immunoblot to determine the expression of each PIPKIβ construct (bottom panel). The right panel shows densitometry values 
for the PI(4,5)P2 band. One representative experiment of two is shown. (F) PIPKIβ∆456 kinase activity is dispensable for prevention of cell polarity. PIPKIβ-, 
PIPKIβ∆456-, or kinase-dead PIPKIβ∆456
K138A-expressing dHL60 cells were stimulated with fMLP and stained with phalloidin (red) to detect F-actin. Quanti-
ﬁ  cation of polarized cells, determined as phalloidin staining at the leading edge, is shown (right panel). (G) PIPKIβ overexpression restores cell polarity 
in PIPKIβ∆456-expressing cells. dHL60 cells were transfected with the indicated plasmids mixtures (pRFP-PIPKIβ and pEGFP; pGFP-PIPKIβ∆456 and pRFP; 
pRFP-PIPKIβ and pGFP-PIPKIβ∆456) at a 1:1 ratio. After stimulation, cells were stained for phospho-ERM (blue). Single-color images are provided as 
supplemental material (available at http://www.jcb.org/cgi/content/full/jcb.200705044/DC1). Only cells showing phospho-ERM staining at the uropod 
were scored as polarized (right panel). The cells shown (A–D, F, and G) are representative of at least 30 recorded in three independent experiments. 
Error bars indicate SEM. Bar, 10 μm.PIPKIβ CONTROLS NEUTROPHIL POLARITY • LACALLE ET AL. 1547
This pattern was not altered in mock- or PIPKIβ-expressing 
cells, but PIPKIβ∆456 overexpression reduced chemoattrac-
tant-induced RhoA activation (Fig. 6 B). siRNA-induced reduc-
tion of endogenous PIPKIβ also diminished fMLP-induced 
RhoA activation in dHL60 cells (Fig. 6 C), suggesting PIPKIβ 
involvement in RhoA activation.
We next analyzed the phosphorylation of MLC (pS
19-MLC), 
a target of the RhoA-ROCK pathway, in fMLP-stimulated cells. 
We found an acute reduction in pS
19-MLC in PIPKIβ∆456-
  expressing cells compared with PIPKIβwt-expressing cells 
(Fig. 6 D); pS
19-MLC levels were recovered in PIPKIβ∆456-
expressing cells by coexpressing PIPKIβwt (Fig. 6 D). We detected 
a slight, nonsignifi  cant reduction in phospho-MLC staining in 
cells expressing the kinase-dead PIPKIβ
K138A mutant (Fig. 6 D). 
As an antibody specifi  city control, fMLP-induced pS
19-MLC 
levels were reduced after cell treatment with the ROCK inhibitor 
Y27632 (Fig. S3 B).
The PIPKI𝗃 C terminus interacts with 
EBP50, ERM proteins, and RhoGDI
We searched for proteins that interact with the 83aa-tail, using 
affi  nity purifi  cation of a dHL60 detergent extract on 83aa-tail 
GST fusion protein (Fig. 7 A). Four bands were selectively re-
tained by the PIPKIβ 83aa-tail, which were identifi  ed by matrix-
assisted laser desorption/ionization-time-of-fl  ight (MALDI-TOF) 
mass spectrometry of tryptic digests as spectrin α, a 110-kD pro-
tein with spectrin β homology, moesin, and EBP50 (also termed 
sodium-proton exchanger regulatory factor 1), an adaptor for 
ERM proteins (Reczek et al., 1997). In addition, the 83aa-tail re-
tained an unidentifi  ed  67-kD protein. Moesin represents more 
than 90% of the ERM proteins expressed in dHL60 cells (Ivetic 
and Ridley, 2004; and unpublished data); it is thus feasible that 
rescue of moesin in the pull-down assay indicates the ability of 
the 83aa-tail to interact with ERM proteins.
Immunofl  uorescence analysis of the proteins that bind the 
83aa-tail indicated homogeneous spectrin α juxtamembrane 
staining in fMLP-stimulated dHL60 cells (unpublished data); in 
contrast, phospho-ERM and EBP50 polarized to the uropod of 
fMLP-stimulated PIPKIβwt-expressing cells (Fig. 7 B). Notably, 
PIPKIβ∆456 overexpression prevented polarization of these 
uropod markers (Fig. 7 C).
We tested 83aa-tail-GST binding to biotin-labeled, in vitro–
translated moesin or EBP50. Recombinant moesin did not bind 
to 83aa-tail-GST (unpublished data), but in vitro–translated 
EBP50 bound very effi  ciently to the 83aa-tail-GST (Fig. 8 A); 
more important, the in vitro–translated moesin FERM (band 4.1 
protein-ezrin-radixin-moesin) domain bound to the 83aa-tail-GST 
protein only in the presence of EBP50 (Fig. 8 A). These results 
suggested that EBP50 might regulate the interaction between 
ERM proteins and the PIPKIβ C terminus in a chemoattractant-
dependent manner.
We analyzed the interaction of EBP50 and ERM proteins 
in PIPKIβwt- and PIPKIβ∆456-expressing cells. ERM proteins 
coprecipitated with PIPKIβwt after chemoattractant stimula-
tion in immunoprecipitation assays; as predicted, this associa-
tion was not observed for PIPKIβ∆456 (Fig. 8 B). Moreover, 
chemoattractant stimulation induced time-dependent association 
between ERM and EBP50, but only in cells overexpressing 
PIPKIβwt (Fig. 8 C); EBP50 appeared as a doublet in these 
immunoprecipitates, probably as a consequence of phosphory-
lation. Together, these results suggest that the PIPKIβ 83aa-tail 
regulates formation of a complex between ERM proteins and 
EBP50 after chemoattractant stimulation.
ERM proteins act upstream of Rho GTPases by interact-
ing with RhoGDI, enabling RhoA activation (Takahashi et al., 
1997). Based on the association between ERM proteins and 
the 83aa-tail, we found that chemoattractants induced co-
precipitation of RhoGDI with overexpressed PIPKIβwt, whereas 
only a small amount PIPKIβ∆456 could be detected in these 
immuno  precipitates (Fig. 8, D and E). Moreover, we did not 
detect ERM-RhoGDI complexes in immunoprecipitates of 
PIPKIβ∆456-expressing cells (Fig. 8 E).
Discussion
Here we identifi  ed uropodal PIPKIβ localization as an impor-
tant step in the organization of signaling involved in neutrophil 
polarity and chemotaxis. We found that (1) PIPKIβ polarized to 
the uropod after chemoattractant stimulation; (2) RNAi-induced 
knockdown of PIPKIβ impaired neutrophil polarity and chemo-
taxis as well as RhoA activation, indicating the relevance of the 
endogenous enzyme in these processes; (3) uropod PIPKIβ lo-
calization required the C-terminal 83aa-tail; (4) catalytically ac-
tive or inactive PIPKIβ mutants lacking the C terminus prevented 
spatial and functional cell asymmetry and gradient sensing; and 
(5) the C-terminal 83aa-tail interacted with different adapters 
including, but not limited to, EBP50, moesin, and RhoGDI.
siRNA attenuation of PIPKIβ levels inhibited dHL60 cell 
polarity, impaired persistence during chemotaxis, and reduced 
chemoattractant-induced RhoA activation, although the effects 
were less dramatic than those observed for the PIPKIβ∆456 
mutant. One explanation for these mild effects is that other 
PIPKI isozymes might compensate for the PIPKIβ defi  ciency. 
Results from PIPKIβ-null mice support this idea; although 
PIPKIβ has an exclusive role in modulating the actin cytoskele-
ton in mast cells, no major phenotypic defects were  reported in 
these mice (Sasaki et al., 2005). The long PIPKIγ
661 isozyme is 
a candidate for PIPKIβ compensation, although a recent report 
suggests that this isoform is not required for G protein–coupled 
receptor-stimulated chemotaxis (Sun et al., 2007). The interplay 
between PIPKIβ and PIPKIγ
661 during leukocyte chemotaxis 
and the identity of their targets require further study.
Activation of ERM proteins requires two signals, PI(4,5)P2 
binding, and threonine phosphorylation within the actin-binding 
domain (Ivetic and Ridley, 2004). PI(4,5)P2 is thought to recruit 
ERM proteins to the membrane by unfolding inactive mono-
mers, whereas phosphorylation is believed to stabilize the active 
open conformation (Fievet et al., 2004). The FERM domain of 
active ERM proteins can then interact with RhoGDI, trigger-
ing RhoA activation (Takahashi et al., 1997); this in turn can 
induce further ERM activation through ROCK- or PIPKI-
dependent mechanisms (Chong et al., 1994; Matsui et al., 1999; 
Santarius et al., 2006). In vitro kinase assays indicate that chemo-
attractants stimulate PIPKIβ-mediated PI(4,5)P2 production. JCB • VOLUME 179 • NUMBER 7 • 2007  1548
Figure 6. PIPKI𝗃 controls signaling at the uropod. (A) PIPKIβwt- and PIPKIβ∆456-expressing dHL60 cells were exposed to uniform fMLP attractant, and 
stained with anti-RhoA antibody (red). Nomarski, red, and green channels are shown. Cells represent at least 15 cells (n = 3). (B) Mock-, PIPKIβwt- and 
PIPKIβ∆456-transfected HEK-293 cells were stimulated in suspension with CXCL12. At the times indicated, RhoA-GTP levels were determined with a lumi-
nometry-based assay. Values were normalized to those obtained in unstimulated cells and expressed as x-fold of induction. (C) Control or PIPKIβ-speciﬁ  c 
siRNA-transfected dHL60 cells were stimulated with fMLP and RhoA-GTP levels determined. Values were normalized to those obtained in unstimulated con-
trol siRNA-transfected cells. For B and C, data are mean ± SEM of values obtained in three independent experiments. (D) GFP-PIPKIβwt-, GFP-PIPKIβ
K138A-, 
and GFP-PIPKIβ∆456-expressing dHL60 cells, and cells coexpressing RFP-PIPKIβwt and GFP-PIPKIβ∆456 were stimulated as in A, and MLC phosphoryla-
tion analyzed by staining with a pS
19-MLC–speciﬁ  c antibody (red or blue, as indicated). (E) Quantiﬁ  cation of the pS
19-MLC staining area of cells in D. Data 
are mean ± SEM of 20–35 cells recorded in three independent experiments. (*, P < 0.05, two-tailed Dunnett’s test). Bar, 10 μm.PIPKIβ CONTROLS NEUTROPHIL POLARITY • LACALLE ET AL. 1549
Local PIPKIβ-mediated PI(4,5)P2 production might trigger 
ERM activation locally, initiating or boosting this feedback loop.
The phenotype observed in cells expressing the kinase-
dead mutant is puzzling, however. Chemotaxing PIPKIβ
K138A-
expressing cells showed defects in tail retraction (Video 4) and 
a severe reduction in speed. Uropod detachment requires RhoA/
ROCK-induced myosin II contraction (Alblas et al., 2001; 
Worthylake et al., 2001), suggesting that PI(4,5)P2 production 
participates in PIPKIβ-mediated RhoA activation. Nonetheless, 
PIPKIβ
K138A expression only minimally affected pS
19-MLC phos-
phorylation, which is controlled by the RhoA/ROCK pathway. 
This result suggests that local PIPKIβ-induced PI(4,5)P2 produc-
tion is dispensable for RhoA activation; alternatively, PIPKIβ 
might regulate dHL60 cell chemotaxis via another mechanism(s) 
besides, or in addition to RhoA activation.
The most severe phenotype was observed in cells express-
ing the PIPKIβ∆456 mutant, which lacks the uropod targeting 
sequence in the 83aa-tail. PIPKIβ∆456-expressing cells cannot 
establish a stable front–rear asymmetry axis, leading to mem-
brane ruffling or AKT-PH recruitment to cell edges up and 
down the gradient. PIPKIβ∆456 expression does not abrogate 
signals associated to the leading edge, but this mutant impaired 
chemo  attractant-induced RhoA activation and pS
19-MLC phos-
phorylation in the uropod. Notably, ERM proteins did not coprecip-
itate detectably with RhoGDI in PIPKIβ∆456-overexpressing 
cells (Fig. 8). Based on these results, PIPKIβ polarization at the 
uropod might be a mechanism for signal  localization at the 
cell posterior.
It is intriguing that these PIPKIβ∆456 effects occurred 
in cells expressing endogenous PIPKIβ, which suggests that 
PIPKIβ∆456 acts as a dominant-negative mutant. Chemo-
attractants stimulated PIPKIβ∆456-mediated PI(4,5)P2 produc-
tion; it is nonetheless unlikely that the PIPKIβ∆456 phenotype 
is a consequence of delocalized PI(4,5)P2 synthesis because the 
kinase-dead PIPKIβ∆456
K138A mutant impedes cell polarity. 
PIPKIβ∆456 cannot engage the EBP50-ERM-RhoGDI complex 
(Fig. 8). The dominant-negative phenotype of the PIPKIβ∆456 
mutant could be explained by assuming that the PIPKIβ N terminus 
or the common kinase domain might interact with other effec-
tors or adaptors critical for neutrophil polarization. PIPKIβ∆456 
would thus sequester these effectors/adaptors, preventing their 
interaction with endogenous PIPKIβ (which is expressed at 
much lower levels than the mutant). In support of this idea, co-
expression of PIPKIβwt restored fMLP-induced polarization 
of PIPKIβ∆456-expressing dHL60 cells (Fig. 5 G). Identifi  ca-
tion of these additional PIPKIβ-interacting proteins will require 
future experiments.
In conclusion, we have determined that PIPKIβ is a new 
element in the regulation of neutrophil polarity and chemotaxis. 
PIPKIβ polarizes at the cell posterior through its C-terminal 
Figure 7. The  PIPKI𝗃 C terminus interacts with moesin and EBP50. (A) Pull-down assays were performed using the 83aa-tail fused to GST, or GST alone. 
Proteins were resolved in SDS-PAGE; proteins bound differentially to GST-83aa-tail and to GST were identiﬁ  ed by MALDI-TOF mass spectrometry. Results 
shown are representative of two independent experiments. (B and C) Localization of endogenous phospho-ERM proteins (p-ERM) and EBP50 in GFP-
PIPKIβwt- (B) and GFP-PIPKIβ∆456-expressing dHL60 cells (C) by immunoﬂ  uorescence. Cells are representative of 30 cells recorded in two independent 
experiments; bar, 10 μm.JCB • VOLUME 179 • NUMBER 7 • 2007  1550
  domain, which interacts with other uropod proteins such as EBP50 
and ERM. Given that EBP50 is a PDZ (postsynaptic density 
protein, disc-large, zonulin-1)-containing protein, it is possible 
that EBP50 links PIPKIβ to a network of PDZ proteins known to 
shape the uropod in other leukocytes (Ludford-Menting et al., 
2005). PIPKIβ might thus participate in several signaling net-
works involved in leukocyte uropod identity.
Materials and methods
Antibodies and reagents
Anti–human PIPKIα, β, and γ, anti-myc clone 9E10, and anti-RhoA anti-
bodies were obtained from Santa Cruz Biotechnology, Inc.; anti-phospho-
ERM, -ERM, -pS
19-MLC, -phospho AKT, and -spectrin αII were from Cell 
Signaling Technology; anti-Rac and anti-AKT from Millipore; anti-EBP50 
from Afﬁ  nity BioReagents; anti-HA from Covance; anti-moesin from BD Bio-
sciences; anti-ezrin from Invitrogen; peroxidase-labeled anti–mouse and 
anti–rabbit IgG from Dako; and biotinylated anti–rabbit IgG and cy2- and 
cy3-conjugated secondary antibodies from Jackson ImmunoResearch Lab-
oratories. Anti-GST antibodies, Tri-reagent, PTX, Ficoll-Hypaque, Ponceau S 
red, ﬁ  bronectin, DMSO, and fMLP were from Sigma-Aldrich; human 
CXCL12 was from PeproTech. The TNT transcription–translation system, 
Transcend Non-Radioactive Translation Detection Systems, trypsin, and 
peroxidase-labeled streptavidin were from Promega.
Cloning and generation of PIPKI𝗃 mutants
cDNAs encoding mouse PIPKIα, β, and γ, and the kinase-dead PIPKIβ
K138A 
mutant were a gift of H. Isihara (University of Geneva, Geneva, Switzer-
land) and were subcloned in pEGFP-C1 (Clontech Laboratories, Inc.), 
pRFP-C3 (a gift of L. Rajendran, Max-Planck-Institute for Molecular Cell Biol-
ogy and Genetics, Dresden, Germany), or pcDNA3.1-HA (a gift of 
T. Fischer; Centro Nacional de Biotecnología/CSIC, Madrid, Spain) to 
generate the GFP-, RFP-, and HA-chimeras, respectively. The deletion and 
Figure 8. The  PIPKI𝗃 C terminus regulates ERM protein interaction with RhoGDI. (A) Equal amounts of GST-83aa-tail and GST proteins were incubated 
with 12 μl of biotinylated EBP50 and/or moesin FERM; bound proteins were analyzed by blotting with peroxidase-labeled streptavidin to detect biotinylated 
proteins (top panel) and Ponceau red for the GST and GST-83aa-tail (bottom panel). Relative migration of in vitro–translated EBP50 and moesin FERM 
domain (1 μl/lane) in the absence of GST proteins is shown (ﬁ  rst and last lanes). (B) HA-tagged PIPKIβwt- and PIPKIβ∆456-expressing HEK-293 cells were 
stimulated in suspension with CXCL12 for the times indicated (in seconds). ERM proteins were immunoprecipitated and bound proteins analyzed sequen-
tially with anti-HA and anti-ERM protein antibodies. Arrows indicate the relative migration of HA-PIPKIβwt- and HA-PIPKIβ∆456 proteins. E indicates cell 
extract. (C) The lysates in B were immunoprecipitated with anti-ERM protein antibody and blotted with anti-EBP50 and -ERM antibodies. (D) HEK-293 cells 
were cotransfected with myc-tagged RhoGDI and either HA-tagged PIPKIβwt or -PIPKIβ∆456, and stimulated in suspension with CXCL12. Cell lysates were 
immunoprecipitated with anti-HA antibodies and bound proteins blotted for RhoGDI (myc tag) and PIPKIβ (HA tag). (E) Cell lysates from CXCL12-stimulated 
HEK-293 cells coexpressing myc-RhoGDI and HA-PIPKIβwt- or HA-PIPKIβ∆456 were immunoprecipitated with anti-myc antibodies, then blotted sequentially 
with anti-HA, -ERM proteins, and -myc antibodies. Arrows indicate the relative migration of HA-PIPKIβwt and HA-PIPKIβ∆456. The blots are representative 
of three independent experiments. PIPKIβ CONTROLS NEUTROPHIL POLARITY • LACALLE ET AL. 1551
swapping mutants were generated using PCR and pfu Turbo DNA polymer-
ase (Stratagene) and cloned in pEGFP-C1, pRFP-C3, and pcDNA3.1-HA 
(from T. Fischer; Centro Nacional de Biotecnología, Madrid, Spain) to ob-
tain the corresponding tag-fusion proteins. The C-terminal fragment of 
PIPKIα (83aa-tail) was subcloned in pEGFP-C1 to generate the GFP chi-
mera and in pGEX-4-T1 (GE Healthcare) for expression as a GST fusion 
protein in Escherichia coli. The ezrin FERM domain, a gift from M. Arpin 
(Institut Curie, Paris, France), was cloned in pcDNA3.1-HA and in pGEX-4-T1. 
The catalytically inactive Gα12
(Q209L/D277N) and Gα13
(Q226L/D294N) mutants 
(UMR cDNA Resource Center) were cloned in the pRV-IRES-GFP bicistronic 
plasmid (Genetrix). Dominant-negative Gα12 and Gα13 mutants were gen-
erated by cloning the C-terminal fragments of these G proteins in 
pCDNA3.1-HA. The Rac PBD was subcloned in pEGFP-C3; the GFP-PLCδ-
PH domain was a gift of C. Schneider and P. Caroni (Friedrich Miescher 
Institute, Basel, Switzerland); myc-tagged RhoGDI was a gift of B. Olofsson 
(Centre National de la Recherche Scientiﬁ  que, Gif-sur-Yvette, France). 
The EBP50 and moesin gene cDNA (Open Biosystems) were cloned in 
pCDNA3.1HA. The moesin FERM domain was ampliﬁ  ed by PCR and cloned 
in pcDNA3.1-HA and in pGEX-4-T1. The GFP-AKT-PH domain and GFP-
RhoN19 have been described (Gómez-Moutón et al., 2004).
Cell culture and transfections
HL60 cells were maintained in RPMI 1640 with 10% FCS and differenti-
ated with 1.3% DMSO for 7 d. Differentiated cells were transfected with 
the indicated plasmids by electroporation (2 × 10
7 cells, 320 mV, 1,000 μF) 
in an electroporator (Bio-Rad Laboratories), or using the T Cell Nucleo-
fector kit (Amaxa Biosystems); protein expression was analyzed 6–12 h 
after transfection by FACS (Beckman Coulter), and live cells isolated on 
Ficoll-Hypaque gradients. Transfection efﬁ  ciency was typically 15–20%. 
Jurkat cells were cultured in RPMI 1640 with 10% FCS and transfected as 
described (Gómez-Moutón et al., 2004). HEK-293 cells were maintained 
in DME with 10% FCS. Cells were transiently transfected with the indicated 
plasmids using the standard calcium phosphate method, and protein ex-
pression analyzed 48 h later (transfection efﬁ  ciency was 70–80%).
siRNA experiments
dHL60 cells were transfected with two human PIPKIβ-speciﬁ  c or non-
speciﬁ  c siRNA duplexes (50 nM; Dharmacon) using Jet-siENDO (Polyplus 
Transfection). The sequences of the PIPKIβ-speciﬁ  c siRNA duplexes were: 
5′-G  G  C  A  G  A  C  A  G  A  U  U  U  C  U  U  A  A  G  U  U  U  -3′ and 5′-U  A  A  G  A  C  A  U  A  C  G  U  C  C-
A  U  U  A  U  U  -3′. In all experiments, a Cy3-labeled nonspeciﬁ  c duplex control 
(Dharmacon) was transfected with control or speciﬁ  c duplexes to determine 
transfection efﬁ  ciency (usually 98–100% by FACS). PIPKIβ silencing was 
analyzed 24 and 48 h after transfection by quantitative RT-PCR using Taqman 
probes (Applied Biosystems) speciﬁ  c for the human PIPKα, β, and γ genes. 
∆Ct values provided by the software of the apparatus were normalized 
using 18S RNA, and the relative mRNA levels calculated using the formula 
2 − (∆Ct sample − ∆Ct control). GAPDH ampliﬁ  cation was performed in 
each experiment as an internal control. PIPKIβ silencing was analyzed 48 h 
after transfection by sequential immunoblotting with anti-PIPKIβ and anti-actin 
(loading control) antibodies.
Time-lapse confocal videomicroscopy and chemotaxis assays
Real-time cell chemotaxis was studied by time-lapse confocal microscopy 
as described (Gómez-Moutón et al., 2004). Starved cells were plated 
(1 h, 37°C) on ﬁ  bronectin-coated chamber coverslips (Nunc) and stimulated 
with fMLP (100 nM) applied with a micropipette at 37°C. Fluorescence 
and phase-contrast images were recorded in a confocal microscope (TCS-
NT; Leica) with a 63× NA1.4 oil plan-Apo objective with an electronic 
zoom of 2 at established time intervals. Brightness and/or contrast were 
adjusted, and videos were processed with ImageJ software (National Insti-
tutes of Health, Bethesda, MD). Motility parameters and cell tracks from 
these videos were obtained using the MetaMorph Imaging System (Meta 
Imaging Software). The directional index was calculated as the net dis-
tance moved toward the chemoattractant source divided by the cumulative 
length of the migration path. Cell velocity was deﬁ  ned as the net distance 
divided by the time used to cover it. Plots showing trajectories of different 
cells were composed in Adobe Photoshop.
For transwell assays, 1–2 × 10
5 PIPKIβ-expressing, Y-27632-
pretreated (10 μM, 1 h; Calbiochem), or siRNA-transfected dHL60 cells were 
seeded in the upper chamber in serum-free medium; lower chambers were 
ﬁ  lled with serum-free medium alone or containing fMLP (100 nM). Trans-
migrated cells were quantiﬁ  ed by FACS after incubation (2.5 h, 37°C). 
The percentage of migrating cells was calculated as the quotient of the 
number of migrating ﬂ  uorescent cells in the lower chamber and the ﬂ  uores-
cent cells in the initial input.
Immunoﬂ  uorescence and cell polarity assays
Serum-starved Jurkat- and dHL60-transfected cells were plated on ﬁ  bro-
nectin-coated slides and, after incubation (1 h, 37°C), were stimulated with 
CXCL12 (100 nM, 10 min, 37°C) or fMLP (100 nM, 3 min, 37°C). After 
washing, plates were ﬁ  xed with 3.7% paraformaldehyde (10 min, 20°C) 
in PBS, permeabilized with 0.1% Triton X-100 (5 min, 20°C), and incu-
bated (1 h, 4°C) with the indicated primary antibody, followed by the ap-
propriate Cy2- or Cy3-conjugated secondary antibody. Samples were 
mounted in Vectashield medium (Vector Laboratories) and images recorded 
in a confocal microscope (Fluoview 10; Olympus) with a 60× 1.4NA oil 
plan-Apo objective, using FV10-ASW 1.6 software (Olympus). Brightness 
and/or contrast were adjusted with ImageJ software. In some experiments, 
starved cells were treated with PTX (0.5 mg/ml, 16 h, 37°C) or Y-27632 
(10 μM, 1 h, 37°C), and plated on Fn-coated slides. PTX and Y-27632 
were maintained throughout the assay.
Cell polarization in siRNA-transfected cells was determined by 
F-actin staining with phalloidin-rhodamine (Invitrogen) and anti-phospho-ERM. 
Cells showing both accumulation of actin at the leading edge and phospho-
ERM at the uropod were scored as polarized. Eight random ﬁ  elds were re-
corded per condition and at least 200 cells were counted per sample in 
three independent experiments.
pSer
19-MLC levels were quantiﬁ  ed as described (Jiménez-Baranda 
et al., 2007). In brief, dHL-60 cells stained with anti-pSer
19-MLC antibody 
and were serially scanned in horizontal sections 0.6 μm apart; section 4 
was used for quantiﬁ  cation. The same black and white threshold was then 
applied to all images collected (upper threshold level 76, lower thresh-
old level 30). The image was scaled (512 pixels = 152.4 μm; pixel/
aspect ratio = 1) and particle measurement automatically performed using 
ImageJ software.
Lipid kinase assays
Serum-starved mock-, HA-PIPKIβ-, HA-PIPKIβ
K138A-, HA-PIPKIβ∆456-, and 
HA-PIPKIβ∆456
K138A-expressing HEK-293 cells were stimulated in suspen-
sion with CXCL12 (100 nM, 1 min, 37°C) for the times indicated. HA-tagged 
enzymes were immunoprecipitated from cell extracts and lipid kinase 
activity was determined as described (Jones et al., 2000). The kinase 
reaction mix (50 μl) contained 200 μM PI4P (Echelon Biosciences), 20 μM 
ATP, 10 mM MgCl2, and 10 μCi [γ
32]ATP (GE Healthcare). Radioactive 
spots with an Rf value corresponding to PI(4,5)P2 were identiﬁ  ed by auto-
radiography after TLC.
The amount of PI(4,5)P2 was measured in cell extracts from mock-, 
PIPKIβ-, and PIPKIβ∆456-expressing HEK-293 cells before and after CXCL12 
stimulation (100 nM, 2 min, 37°C) using the PI(4,5)P2 Mass Strip kit (Echelon 
Biosciences) according to the supplier’s protocol.
Rho activation assay
RhoA activity was determined using the luminescence-based G-LISA RhoA 
Activation Assay Biochem kit (Cytoskeleton, Inc.). PIPKIβ-speciﬁ  c and mis-
matched siRNA transfected-dHL60 cells or mock-, PIPKIβ-, or PIPKIβ∆456-
expressing HEK-293 cells were starved and maintained in suspension. 
Cells were stimulated with fMLP (100 nM) or CXCL12 (100 nM) for the 
indicated times and assayed according to the supplier’s protocol.
In vitro and in vivo analysis of PIPKI𝗃 interactions
For pull-down assays, GST-83aa-tail or GST proteins were produced in 
E. coli and puriﬁ  ed using glutathione Sepharose 4B (GE Healthcare). dHL60 
cells (2 × 10
8) were stimulated with fMLP (100 nM, 5 min, 37°C) and ex-
tracts were prepared immediately with RIPA buffer (50 mM Tris-HCl, pH 
7.5, 0.15 M NaCl, 0.1% SDS, 0.5% deoxycholate, and 1% NP-40). After 
preclearing with GST, cell extracts were incubated (overnight, 4°C) with 
GST-83aa-tail or GST bound to glutathione Sepharose. Beads were washed 
and retained proteins eluted with SDS sample buffer; after boiling for 
5 min, proteins were resolved by SDS-PAGE and stained with Coomassie 
blue. Protein identiﬁ  cation was performed by the Proteomics Core Facility 
(see below).
Pull-down assays were also performed with in vitro–transcribed 
and –translated EBP50, moesin, and HA-moesin FERM domain using 
the TNT system (T7 promoter), incorporating biotinylated lysine residues in 
the nascent proteins. Interaction of the GST-83aa-tail or GST with the prey 
proteins was performed in binding buffer (PBS, 1% BSA, 0.02% Triton 
X-100) for 1 h at 4°C. After washing with PBS containing 0.05% Triton 
X-100, the proteins were eluted in SDS sample buffer and analyzed by 
  immunoblot using peroxidase-labeled streptavidin. Before immunoblotting, 
nitrocellulose membranes were stained with Ponceau S red to visualize 
GST proteins.JCB • VOLUME 179 • NUMBER 7 • 2007  1552
For immunoprecipitation, serum-starved HEK-293 cells transfected 
with PIPKIβ or PIPKIβ∆456 were stimulated in suspension with 100 nM 
CXCL12 (37°C) for the indicated times, placed on ice, washed with ice-
cold PBS, and lysed with RIPA buffer. Cell extracts (300 μg) were immuno-
precipitated (2 h, 4°C) with anti-HA, -ERM, -myc, or –mouse IgG antibody, 
followed by incubation (1 h, 4°C) with Gamma-Bind Plus Sepharose (GE 
Healthcare). Immunoprecipitates were resolved in SDS-PAGE and ana-
lyzed by immunoblot with anti-HA, -ERM, and -myc antibodies.
Proteomic techniques
Proteins from stained one-dimensional polyacrylamide gels were excised 
and processed in 96-well plates in a Proteineer DP (Bruker Daltonics). 
For protein digestion, gel plugs were washed with 50 mM NH4HCO3 and 
treated with acetonitrile before reduction (10 mM DTT in 25 mM NH4HCO3) 
and alkylation (55 mM iodoacetamide in 50 mM NH4HCO3). Proteins 
were trypsin-digested (15 ng/μl in 25 mM NH4HCO3, 4 h, 37°C). 
Peptides were eluted from gel pieces with 0.5% triﬂ  uoroacetic acid (TFA) in 
water (30 min, 25°C). Peptides were analyzed by MALDI-TOF MS; 0.5 μl 
matrix solution (5 mg/ml 2,5-dihydrobenzoic acid in 33% [vol/vol] aque-
ous acetonitrile and 0.1% [vol/vol] TFA) was added to a 600-μm Anchor-
Chip MALDI target (Bruker Daltonics) and dried at room temperature. 
A 0.5 μl aliquot of each peptide mixture was deposited onto matrix spots 
and dried.
MALDI peptide mass ﬁ  ngerprinting was acquired on a Bruker Reﬂ  ex 
IV MALDI-TOF mass spectrometer with SCOUT source in positive ion reﬂ  ec-
tor mode (ion acceleration voltage 23 kV). Spectra were acquired with 
FlexControl 2.4 and processed with Flex Analysis 2.4. Equipment was 
externally calibrated using protonated mass signals from a peptide mixture 
(1,000–3,500 m/z range). For peak list generation, each spectrum was 
internally calibrated with two known trypsin autoproteolysis peptides; typi-
cal mass measurement accuracy was ±30 ppm (800–3,000 m/z range). 
Data analysis parameters were a signal-to-noise threshold of 20 and reso-
lution >4,000.
For protein identiﬁ  cation, the tryptic peptide masses were batch pro-
cessed and searched against the nonredundant National Center for Bio-
technology Information (NCBI) database using Mascot 2.1 (Matrix Science) 
through the Bruker Biotools 2.0 interface. Search parameters were carb-
amidomethyl cysteine (ﬁ  xed modiﬁ  cation), oxidized methionines (variable 
modiﬁ  cation), peptide mass tolerance of 80 ppm, with one missed cleav-
age site allowed. For all proteins, the probability-based Mowse scores 
were greater than the minimum score ﬁ  xed as signiﬁ  cant (P < 0.02).
Statistical analysis
Data are expressed as mean ± SEM. Dunnett two-tailed or Student’s 
two-tailed t tests were used to compare differences between groups in vari-
ous experiments.
Online supplemental material
Figure S1 shows the analysis of HA-tagged PIPKIβ localization in dHL60 
neutrophil-like cells and Jurkat T cells, as well as additional images for 
endogenous PIPKI isoforms and the kinase-dead PIPKIβ
K138A mutant in fMLP-
stimulated cells. Figure S2 shows the analysis of PI(4,5)P2 and PIP3 levels 
in PIPKIβ-expressing cells. Figure S3 shows the analysis of RhoA activity in 
dHL60 and HEK-293 cells stimulated with fMLP and CXCL12, respectively, 
as well as analysis of antibody speciﬁ  city for pS
19-MLC. Video 1 shows 
PIPKIβ polarization to the uropod during dHL60 cell chemotaxis. Video 2 
shows that PIPKIα does not polarize during dHL60 cell chemotaxis. Video 3 
shows the homogeneous distribution of PIPKIγ
635 during dHL60 cell chemo-
taxis. Video 4 shows distribution of the kinase-dead PIPKIβ
K138A mutant dur-
ing dHL60 cell chemotaxis. Video 5 shows the cellular localization of the 
C terminus–deleted PIPKIγ
1–502 mutant in chemotaxing dHL60 cells. Video 6 
shows the dynamics of the GFP-tagged chimera formed by the C terminus–
deleted PIPKIγ
1–502 mutant and the PIPKIβ C terminus (PIPKIγ
1–502β
455–539), 
during chemotaxis toward fMLP. Video 7 shows time-lapse confocal im-
ages of dHL60 cells coexpressing AKT-PH-GFP and RFP-PIPKIβwt migrating 
toward fMLP. Video 8 shows that overexpression of the PIPKIβ∆456 mutant 
impedes polarization of PI3K signaling in directionally stimulated dHL60 
cells. Video 9 shows that PIPKIβwt-expressing dHL60 cells persistently po-
larize Rac signaling during chemotaxis. Video 10 shows that PIPKIβ∆456 
overexpression inhibits polarization of Rac signaling in directionally stimu-
lated dHL60 cells. Online supplemental material is available at http://
www.jcb.org/cgi/content/full/jcb.200705044/DC1.
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